You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NameLithium
Accession NumberDB01356
TypeSmall Molecule
GroupsApproved
DescriptionLithium was used during the 19th century to treat gout. Lithium salts such as lithium carbonate (Li2CO3), lithium citrate, and lithium orotate are mood stabilizers. They are used in the treatment of bipolar disorder, since unlike most other mood altering drugs, they counteract both mania and depression. Lithium can also be used to augment other antidepressant drugs. It is also sometimes prescribed as a preventive treatment for migraine disease and cluster headaches. The active principle in these salts is the lithium ion Li+, which having a smaller diameter, can easily displace K+ and Na+ and even Ca+2, in spite of its greater charge, occupying their sites in several critical neuronal enzymes and neurotransmitter receptors.
Structure
Thumb
Synonyms
Li(+)
Lithium cation
Lithium ion
Lithium, ion
Lithium, ion (li1+)
External Identifiers Not Available
Approved Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Carbolith Cap 150mgCapsule150 mgOralValeant Canada Lp Valeant Canada S.E.C.1979-12-31Not applicableCanada
Carbolith Cap 300mgCapsule300 mgOralValeant Canada Lp Valeant Canada S.E.C.1971-12-31Not applicableCanada
Carbolith Capsules 600mgCapsule600 mgOralValeant Canada Lp Valeant Canada S.E.C.1992-12-31Not applicableCanada
Dom-lithium CarbonateCapsule300 mgOralDominion PharmacalNot applicableNot applicableCanada
Dom-lithium CarbonateCapsule600 mgOralDominion PharmacalNot applicableNot applicableCanada
Dom-lithium CarbonateCapsule150 mgOralDominion PharmacalNot applicableNot applicableCanada
Duralith Tab 300mgTablet, extended release300 mgOralJanssen Inc1985-12-312010-02-12Canada
Euro LithiumCapsule150 mgOralEuro Pharm International Canada Inc2008-02-262013-07-10Canada
Euro LithiumCapsule300 mgOralEuro Pharm International Canada Inc2008-02-262013-07-10Canada
LithaneCapsule300 mgOralErfa Canada 2012 Inc1979-12-31Not applicableCanada
LithaneCapsule150 mgOralErfa Canada 2012 Inc1993-12-31Not applicableCanada
LithiumSolution8 meq/5mLOralRoxane Laboratories, Inc1982-04-292016-10-13Us
LithiumSolution8 meq/5mLOralCardinal Health1982-04-292016-12-02Us
LithiumSolution8 meq/5mLOralWest Ward Pharmaceuticals Corp1980-12-23Not applicableUs
LithiumSolution300 mg/5mLOralPrecision Dose Inc.2012-10-25Not applicableUs
Lithium CarbonateCapsule, gelatin coated300 mg/1OralContract Pharmacy Services Pa2010-04-06Not applicableUs
Lithium CarbonateCapsule, gelatin coated300 mg/1OralWest Ward Pharmaceuticals Corp1980-11-26Not applicableUs
Lithium CarbonateCapsule, gelatin coated300 mg/1OralREMEDYREPACK INC.2013-03-18Not applicableUs
Lithium CarbonateCapsule, gelatin coated150 mg/1OralWest Ward Pharmaceuticals Corp1987-01-28Not applicableUs
Lithium CarbonateCapsule, gelatin coated300 mg/1OralCardinal Health1987-07-28Not applicableUs
Lithium CarbonateCapsule, gelatin coated300 mg/1OralState of Florida DOH Central Pharmacy2009-07-01Not applicableUs
Lithium CarbonateCapsule, gelatin coated300 mg/1OralAphena Pharma Solutions Tennessee, Inc.1980-11-26Not applicableUs
Lithium CarbonateCapsule, gelatin coated600 mg/1OralWest Ward Pharmaceuticals Corp1987-01-28Not applicableUs
Lithium CarbonateCapsule, gelatin coated300 mg/1OralNcs Health Care Of Ky, Inc Dba Vangard Labs1980-11-26Not applicableUs
Lithium CarbonateTablet300 mg/1OralREMEDYREPACK INC.2013-05-07Not applicableUs
Lithium CarbonateCapsule, gelatin coated300 mg/1OralWest Ward Pharmaceuticals Corp1980-11-26Not applicableUs
Lithium CarbonateTablet300 mg/1OralCardinal Health1982-01-29Not applicableUs
Lithium CarbonateCapsule, gelatin coated150 mg/1OralAphena Pharma Solutions Tennessee, Inc.1987-01-28Not applicableUs
Lithium CarbonateCapsule, gelatin coated150 mg/1OralNcs Health Care Of Ky, Inc Dba Vangard Labs1987-01-28Not applicableUs
Lithium CarbonateTablet300 mg/1OralWest Ward Pharmaceuticals Corp1982-06-14Not applicableUs
Lithium CarbonateCapsule, gelatin coated150 mg/1OralWest Ward Pharmaceuticals Corp1987-01-28Not applicableUs
Lithium CarbonateCapsule, gelatin coated300 mg/1OralTYA Pharmaceuticals1980-11-26Not applicableUs
Lithium CarbonateTablet300 mg/1OralWest Ward Pharmaceuticals Corp1982-01-29Not applicableUs
Lithium CarbonateCapsule, gelatin coated150 mg/1OralREMEDYREPACK INC.2006-11-14Not applicableUs
Lithium CarbonateTablet300 mg/1OralSTAT Rx USA LLC1982-01-29Not applicableUs
Lithium CarbonateCapsule, gelatin coated600 mg/1OralWest Ward Pharmaceuticals Corp1987-01-28Not applicableUs
Lithizine Cap 150mgCapsule150 mgOralLabs Maney Paul Labs, Division Of 471449 (Ont) Ltee/Ltd.1975-12-311997-08-19Canada
Lithizine Cap 300mgCapsule300 mgOralLabs Maney Paul Labs, Division Of 471449 (Ont) Ltee/Ltd.1975-12-311997-08-19Canada
LithmaxTablet, extended release300 mgOralAa Pharma Inc2005-04-06Not applicableCanada
LithobidTablet, film coated, extended release300 mg/1OralNOVEN THERAPEUTICS, LLC1979-04-272016-10-13Us
LithobidTablet, film coated, extended release300 mg/1OralANI Pharmaceuticals, Inc.2014-07-01Not applicableUs
Pal-lithium CarbonateCapsule600 mgOralPaladin Labs Inc1998-03-032007-08-03Canada
Pal-lithium CarbonateCapsule150 mgOralPaladin Labs Inc1998-03-032007-08-03Canada
Pal-lithium CarbonateCapsule300 mgOralPaladin Labs Inc1998-03-032007-08-03Canada
PHL-lithium CarbonateCapsule600 mgOralPharmel Inc1998-02-172014-09-08Canada
PHL-lithium CarbonateCapsule150 mgOralPharmel Inc1998-02-172014-09-08Canada
PHL-lithium CarbonateCapsule300 mgOralPharmel Inc1998-02-172014-09-08Canada
PMS-lithium Carbonate - Cap 150mgCapsule150 mgOralPharmascience Inc1996-12-31Not applicableCanada
PMS-lithium Carbonate - Cap 300mgCapsule300 mgOralPharmascience Inc1996-12-31Not applicableCanada
PMS-lithium Carbonate - Cap 600mgCapsule600 mgOralPharmascience Inc1996-12-31Not applicableCanada
PMS-lithium CitrateSyrup8 mmolOralPharmascience Inc1994-12-31Not applicableCanada
Approved Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Apo-lithium CarbonateCapsule300 mgOralApotex Inc2001-02-12Not applicableCanada
Apo-lithium CarbonateCapsule150 mgOralApotex Inc2001-02-12Not applicableCanada
Lithium CarbonateTablet, extended release450 mg/1OralMajor Pharmaceuticals2003-06-17Not applicableUs
Lithium CarbonateCapsule300 mg/1OralPhysicians Total Care, Inc.1995-01-16Not applicableUs
Lithium CarbonateCapsule300 mg/1OralTYA Pharmaceuticals2009-12-15Not applicableUs
Lithium CarbonateTablet, extended release450 mg/1OralAvera Mc Kennan Hospital2015-05-27Not applicableUs
Lithium CarbonateCapsule150 mg/1OralREMEDYREPACK INC.2015-10-13Not applicableUs
Lithium CarbonateTablet, extended release450 mg/1OralWest ward Pharmaceutical Corp2002-09-06Not applicableUs
Lithium CarbonateTablet, extended release450 mg/1OralMylan Institutional Inc.2012-04-20Not applicableUs
Lithium CarbonateCapsule150 mg/1OralGolden State Medical Supply, Inc.2015-08-04Not applicableUs
Lithium CarbonateCapsule600 mg/1OralAmerican Health Packaging2015-03-31Not applicableUs
Lithium CarbonateTablet, extended release300 mg/1OralWest Ward Pharmaceuticals Corp.2004-10-28Not applicableUs
Lithium CarbonateCapsule300 mg/1OralContract Pharmacy Services Pa2010-04-06Not applicableUs
Lithium CarbonateTablet, film coated, extended release300 mg/1OralA S Medication Solutions2010-12-27Not applicableUs
Lithium CarbonateCapsule300 mg/1OralCamber Pharmaceuticals Inc.2009-12-15Not applicableUs
Lithium CarbonateTablet, extended release300 mg/1OralCardinal Health2004-10-28Not applicableUs
Lithium CarbonateCapsule300 mg/1Oralbryant ranch prepack2003-03-01Not applicableUs
Lithium CarbonateCapsule300 mg/1OralGlenmark Pharmaceuticals Inc., Usa2009-02-03Not applicableUs
Lithium CarbonateTablet, extended release450 mg/1OralREMEDYREPACK INC.2011-03-14Not applicableUs
Lithium CarbonateCapsule600 mg/1OralWest Ward Pharmaceuticals Corp2002-05-01Not applicableUs
Lithium CarbonateCapsule300 mg/1OralState of Florida DOH Central Pharmacy2009-07-01Not applicableUs
Lithium CarbonateCapsule150 mg/1OralMajor Pharmaceuticals2003-02-24Not applicableUs
Lithium CarbonateCapsule150 mg/1OralPhysicians Total Care, Inc.2005-12-05Not applicableUs
Lithium CarbonateCapsule150 mg/1OralHetero Drugs Limited2009-09-25Not applicableUs
Lithium CarbonateTablet, extended release300 mg/1OralAvera Mc Kennan Hospital2015-04-16Not applicableUs
Lithium CarbonateTablet, extended release300 mg/1OralRising Pharmaceuticals, Inc.2016-01-01Not applicableUs
Lithium CarbonateTablet300 mg/1OralWest ward Pharmaceutical Corp2010-12-28Not applicableUs
Lithium CarbonateTablet, film coated, extended release300 mg/1OralMylan Institutional Inc.2012-08-10Not applicableUs
Lithium CarbonateCapsule300 mg/1OralGolden State Medical Supply, Inc.2015-08-04Not applicableUs
Lithium CarbonateTablet, extended release450 mg/1OralCarilion Materials Management2004-01-05Not applicableUs
Lithium CarbonateTablet, film coated, extended release300 mg/1OralMylan Pharmaceuticals Inc.2012-07-02Not applicableUs
Lithium CarbonateTablet, extended release300 mg/1OralAmerican Health Packaging2014-10-13Not applicableUs
Lithium CarbonateTablet, film coated, extended release300 mg/1OralREMEDYREPACK INC.2016-01-19Not applicableUs
Lithium CarbonateCapsule600 mg/1OralCamber Pharmaceuticals Inc.2009-12-15Not applicableUs
Lithium CarbonateTablet, extended release450 mg/1OralCardinal Health2003-06-17Not applicableUs
Lithium CarbonateCapsule300 mg/1OralMc Kesson Packaging Services A Business Unit Of Mc Kesson Corporation2007-07-19Not applicableUs
Lithium CarbonateCapsule600 mg/1OralGlenmark Pharmaceuticals Inc., Usa2009-02-03Not applicableUs
Lithium CarbonateCapsule300 mg/1OralREMEDYREPACK INC.2012-08-15Not applicableUs
Lithium CarbonateTablet, film coated, extended release300 mg/1OralNcs Health Care Of Ky, Inc Dba Vangard Labs2004-10-28Not applicableUs
Lithium CarbonateCapsule300 mg/1OralState of Florida DOH Central Pharmacy2009-07-01Not applicableUs
Lithium CarbonateCapsule150 mg/1OralREMEDYREPACK INC.2013-03-182016-03-12Us
Lithium CarbonateTablet, extended release300 mg/1OralPhysicians Total Care, Inc.2005-03-01Not applicableUs
Lithium CarbonateCapsule300 mg/1OralHetero Drugs Limited2009-09-25Not applicableUs
Lithium CarbonateTablet, film coated, extended release300 mg/1OralAmerican Health Packaging2012-03-052015-12-29Us
Lithium CarbonateTablet, film coated, extended release300 mg/1OralGlenmark Pharmaceuticals Inc., Usa2010-12-27Not applicableUs
Lithium CarbonateCapsule150 mg/1OralWest Ward Pharmaceuticals Corp2003-03-01Not applicableUs
Lithium CarbonateCapsule300 mg/1OralREMEDYREPACK INC.2013-02-09Not applicableUs
Lithium CarbonateTablet, extended release300 mg/1OralCarilion Materials Management2004-10-28Not applicableUs
Lithium CarbonateTablet, extended release450 mg/1OralMylan Pharmaceuticals Inc.2012-08-09Not applicableUs
Lithium CarbonateTablet, extended release450 mg/1OralAmerican Health Packaging2014-01-13Not applicableUs
Lithium CarbonateCapsule300 mg/1OralREMEDYREPACK INC.2016-03-11Not applicableUs
Lithium CarbonateCapsule300 mg/1OralProficient Rx LP2009-12-15Not applicableUs
Lithium CarbonateCapsule300 mg/1OralAidarex Pharmaceuticals LLC2009-12-15Not applicableUs
Lithium CarbonateCapsule150 mg/1OralTYA Pharmaceuticals2009-12-15Not applicableUs
Lithium CarbonateCapsule300 mg/1OralClinical Solutions Wholesale2009-12-15Not applicableUs
Lithium CarbonateCapsule300 mg/1OralMajor Pharmaceuticals2003-02-24Not applicableUs
Lithium CarbonateCapsule300 mg/1OralState of Florida DOH Central Pharmacy2014-01-01Not applicableUs
Lithium CarbonateTablet, film coated, extended release300 mg/1OralHeritage Pharmaceuticals Inc.2013-03-30Not applicableUs
Lithium CarbonateCapsule150 mg/1OralCamber Pharmaceuticals Inc.2009-12-15Not applicableUs
Lithium CarbonateTablet, extended release450 mg/1OralPhysicians Total Care, Inc.2005-06-22Not applicableUs
Lithium CarbonateCapsule600 mg/1OralHetero Drugs Limited2009-09-25Not applicableUs
Lithium CarbonateCapsule150 mg/1OralGlenmark Pharmaceuticals Inc., Usa2009-02-03Not applicableUs
Lithium CarbonateTablet, extended release300 mg/1OralREMEDYREPACK INC.2009-09-17Not applicableUs
Lithium CarbonateCapsule300 mg/1OralWest Ward Pharmaceuticals Corp2003-03-01Not applicableUs
Lithium CarbonateCapsule150 mg/1OralREMEDYREPACK INC.2013-05-08Not applicableUs
Lithium CarbonateTablet300 mg/1OralSun Pharmaceutical Industries Limited2010-07-08Not applicableUs
Lithium CarbonateCapsule300 mg/1OralHikma Pharmaceutical2002-06-27Not applicableUs
Lithium CarbonateCapsule150 mg/1OralAmerican Health Packaging2015-03-31Not applicableUs
Lithium CarbonateTablet, extended release450 mg/1OralWest Ward Pharmaceuticals Corp.2004-01-05Not applicableUs
Lithium CarbonateCapsule300 mg/1OralPd Rx Pharmaceuticals, Inc.2003-03-01Not applicableUs
Lithium Carbonate ERTablet450 mg/1OralREMEDYREPACK INC.2016-06-20Not applicableUs
Lithium Carbonate ERTablet450 mg/1OralClinical Solutions Wholesale, Llc2015-06-08Not applicableUs
Lithium Carbonate ERTablet450 mg/1OralGlenmark Pharmaceuticals Inc., Usa2011-02-14Not applicableUs
Lithium Hydroxide MonohydrateSolution8 meq/5mLOralMorton Grove Pharmaceuticals, Inc.1986-05-21Not applicableUs
Approved Over the Counter ProductsNot Available
Unapproved/Other Products Not Available
International Brands
NameCompany
EskalithNot Available
LithoTabNot Available
Brand mixturesNot Available
Salts
Name/CASStructureProperties
Lithium carbonate
554-13-2
Thumb
  • InChI Key: XGZVUEUWXADBQD-UHFFFAOYSA-L
  • Monoisotopic Mass: 74.01675074
  • Average Mass: 73.89
DBSALT001075
Lithium citrate
6080-58-6
Thumb
  • InChI Key: HXGWMCJZLNWEBC-UHFFFAOYSA-K
  • Monoisotopic Mass: 282.09379656
  • Average Mass: 281.98
DBSALT001430
Lithium hydroxide monohydrate
1310-66-3
Thumb
  • InChI Key: GLXDVVHUTZTUQK-UHFFFAOYSA-M
  • Monoisotopic Mass: 42.02930778
  • Average Mass: 41.96
DBSALT001239
Categories
UNII8H8Z5UER66
CAS number7439-93-2
WeightAverage: 6.941
Monoisotopic: 7.016004049
Chemical FormulaLi
InChI KeyHBBGRARXTFLTSG-UHFFFAOYSA-N
InChI
InChI=1S/Li/q+1
IUPAC Name
lithium(1+) ion
SMILES
[Li+]
Pharmacology
IndicationLithium is used as a mood stabilizer, and is used for treatment of depression and mania. It is often used in bipolar disorder treatment.
Structured Indications
PharmacodynamicsAlthough lithium has been used for over 50 years in treatment of bipolar disorder, the mechanism of action is still unknown. Lithium's therapeutic action may be due to a number of effects, ranging from inhibition of enzymes such as glycogen synthase kinase 3, inositol phosphatases, or modulation of glutamate receptors.
Mechanism of actionThe precise mechanism of action of Li+ as a mood-stabilizing agent is currently unknown. It is possible that Li+ produces its effects by interacting with the transport of monovalent or divalent cations in neurons. An increasing number of scientists have come to the conclusion that the excitatory neurotransmitter glutamate is the key factor in understanding how lithium works. Lithium has been shown to change the inward and outward currents of glutamate receptors (especially GluR3), without a shift in reversal potential. Lithium has been found to exert a dual effect on glutamate receptors, acting to keep the amount of glutamate active between cells at a stable, healthy level, neither too much nor too little. It is postulated that too much glutamate in the space between neurons causes mania, and too little, depression. Another mechanism by which lithium might help to regulate mood include the non-competitive inhibition of an enzyme called inositol monophosphatase. Alternately lithium's action may be enhanced through the deactivation of the GSK-3B enzyme. The regulation of GSK-3B by lithium may affect the circadian clock. GSK-3 is known for phosphorylating and thus inactivating glycogen synthase. GSK-3B has also been implicated in the control of cellular response to damaged DNA. GSK-3 normally phosphorylates beta catenin, which leads to beta catenin degratation. When GSK-3 is inhibited, beta catenin increases and transgenic mice with overexpression of beta catenin express similar behaviour to mice treated with lithium. These results suggest that increase of beta catenin may be a possible pathway for the therapeutic action of lithium.
TargetKindPharmacological actionActionsOrganismUniProt ID
Glycogen synthase kinase-3 betaProteinunknown
inhibitor
HumanP49841 details
Inositol monophosphatase 1Proteinunknown
inhibitor
HumanP29218 details
Inositol monophosphatase 2Proteinunknown
inhibitor
HumanO14732 details
Glutamate receptor 3Proteinunknown
potentiator
HumanP42263 details
Related Articles
AbsorptionNot Available
Volume of distributionNot Available
Protein bindingNot Available
MetabolismNot Available
Route of eliminationNot Available
Half lifeNot Available
ClearanceNot Available
ToxicityNot Available
Affected organismsNot Available
PathwaysNot Available
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
Interactions
Drug Interactions
DrugInteractionDrug group
1,1,1,2 TetrafluoroethaneThe risk or severity of adverse effects can be increased when Lithium is combined with 1,1,1,2 Tetrafluoroethane.Investigational
2,5-Dimethoxy-4-ethylamphetamineLithium may decrease the stimulatory activities of 2,5-Dimethoxy-4-ethylamphetamine.Experimental, Illicit
3,4-MethylenedioxyamphetamineLithium may decrease the stimulatory activities of 3,4-Methylenedioxyamphetamine.Experimental, Illicit
3,4-MethylenedioxymethamphetamineLithium may decrease the stimulatory activities of 3,4-Methylenedioxymethamphetamine.Experimental, Illicit
4-Bromo-2,5-dimethoxyamphetamineLithium may decrease the stimulatory activities of 4-Bromo-2,5-dimethoxyamphetamine.Experimental, Illicit
7-NitroindazoleThe risk or severity of adverse effects can be increased when Lithium is combined with 7-Nitroindazole.Experimental
7,8-DICHLORO-1,2,3,4-TETRAHYDROISOQUINOLINEThe risk or severity of adverse effects can be increased when 7,8-DICHLORO-1,2,3,4-TETRAHYDROISOQUINOLINE is combined with Lithium.Experimental
AceclofenacThe serum concentration of Lithium can be increased when it is combined with Aceclofenac.Approved
AcepromazineLithium may increase the neurotoxic activities of Acepromazine.Approved, Vet Approved
AceprometazineLithium may increase the neurotoxic activities of Aceprometazine.Approved
AcetazolamideThe serum concentration of Lithium can be decreased when it is combined with Acetazolamide.Approved, Vet Approved
AcetophenazineLithium may increase the neurotoxic activities of Acetophenazine.Approved
AcetovanilloneThe serum concentration of Lithium can be increased when it is combined with Acetovanillone.Investigational
Acetylsalicylic acidThe serum concentration of Lithium can be increased when it is combined with Acetylsalicylic acid.Approved, Vet Approved
AdapaleneThe serum concentration of Lithium can be increased when it is combined with Adapalene.Approved
adipiplonThe risk or severity of adverse effects can be increased when Lithium is combined with adipiplon.Investigational
AgomelatineThe risk or severity of adverse effects can be increased when Lithium is combined with Agomelatine.Approved, Investigational
AlfaxaloneThe risk or severity of adverse effects can be increased when Lithium is combined with Alfaxalone.Vet Approved
AlfentanilThe risk or severity of adverse effects can be increased when Alfentanil is combined with Lithium.Approved, Illicit
AlmotriptanThe risk or severity of adverse effects can be increased when Almotriptan is combined with Lithium.Approved, Investigational
AlphacetylmethadolThe risk or severity of adverse effects can be increased when Lithium is combined with Alphacetylmethadol.Experimental, Illicit
AlprazolamThe risk or severity of adverse effects can be increased when Alprazolam is combined with Lithium.Approved, Illicit, Investigational
Ambroxol acefyllinateThe serum concentration of Lithium can be decreased when it is combined with Ambroxol acefyllinate.Experimental
AmineptineLithium may increase the neurotoxic activities of Amineptine.Illicit, Withdrawn
AminophyllineThe serum concentration of Lithium can be decreased when it is combined with Aminophylline.Approved
AmiodaroneLithium may increase the QTc-prolonging activities of Amiodarone.Approved, Investigational
AmisulprideThe risk or severity of adverse effects can be increased when Lithium is combined with Amisulpride.Approved, Investigational
AmitriptylineLithium may increase the neurotoxic activities of Amitriptyline.Approved
AmobarbitalThe risk or severity of adverse effects can be increased when Amobarbital is combined with Lithium.Approved, Illicit
AmoxapineThe risk or severity of adverse effects can be increased when Amoxapine is combined with Lithium.Approved
AmperozideLithium may increase the neurotoxic activities of Amperozide.Experimental
AmphetamineLithium may decrease the stimulatory activities of Amphetamine.Approved, Illicit
AnagrelideLithium may increase the QTc-prolonging activities of Anagrelide.Approved
AnisodamineThe serum concentration of Lithium can be increased when it is combined with Anisodamine.Investigational
AntipyrineThe serum concentration of Lithium can be increased when it is combined with Antipyrine.Approved
ApremilastThe serum concentration of Lithium can be increased when it is combined with Apremilast.Approved, Investigational
AripiprazoleLithium may increase the neurotoxic activities of Aripiprazole.Approved, Investigational
Arsenic trioxideLithium may increase the QTc-prolonging activities of Arsenic trioxide.Approved, Investigational
ArtemetherLithium may increase the QTc-prolonging activities of Artemether.Approved
ArticaineThe risk or severity of adverse effects can be increased when Lithium is combined with Articaine.Approved
AsenapineLithium may increase the neurotoxic activities of Asenapine.Approved
Atracurium besylateLithium may increase the neuromuscular blocking activities of Atracurium besylate.Approved
AzaperoneLithium may increase the neurotoxic activities of Azaperone.Vet Approved
AzapropazoneThe serum concentration of Lithium can be increased when it is combined with Azapropazone.Withdrawn
AzelastineLithium may increase the central nervous system depressant (CNS depressant) activities of Azelastine.Approved
AzelastineThe serum concentration of Lithium can be increased when it is combined with Azelastine.Approved
Azilsartan medoxomilThe serum concentration of Lithium can be increased when it is combined with Azilsartan medoxomil.Approved
AzithromycinLithium may increase the QTc-prolonging activities of Azithromycin.Approved
BaclofenThe risk or severity of adverse effects can be increased when Lithium is combined with Baclofen.Approved
BalsalazideThe serum concentration of Lithium can be increased when it is combined with Balsalazide.Approved, Investigational
BarbitalThe risk or severity of adverse effects can be increased when Lithium is combined with Barbital.Illicit
BedaquilineLithium may increase the QTc-prolonging activities of Bedaquiline.Approved
BenazeprilThe serum concentration of Lithium can be increased when it is combined with Benazepril.Approved, Investigational
BendroflumethiazideBendroflumethiazide may decrease the excretion rate of Lithium which could result in a higher serum level.Approved
BenmoxinThe risk or severity of adverse effects can be increased when Benmoxin is combined with Lithium.Withdrawn
BenoxaprofenThe serum concentration of Lithium can be increased when it is combined with Benoxaprofen.Withdrawn
BenperidolLithium may increase the neurotoxic activities of Benperidol.Investigational
BenzocaineThe risk or severity of adverse effects can be increased when Benzocaine is combined with Lithium.Approved
BenzphetamineLithium may decrease the stimulatory activities of Benzphetamine.Approved, Illicit
Benzyl alcoholThe risk or severity of adverse effects can be increased when Lithium is combined with Benzyl alcohol.Approved
Betulinic AcidThe serum concentration of Lithium can be increased when it is combined with Betulinic Acid.Investigational
BifeprunoxLithium may increase the neurotoxic activities of Bifeprunox.Investigational
BrexpiprazoleLithium may increase the neurotoxic activities of Brexpiprazole.Approved
BrimonidineThe risk or severity of adverse effects can be increased when Lithium is combined with Brimonidine.Approved
BrimonidineBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Lithium.Approved
BrinzolamideThe serum concentration of Lithium can be decreased when it is combined with Brinzolamide.Approved
BromazepamThe risk or severity of adverse effects can be increased when Lithium is combined with Bromazepam.Approved, Illicit
BromfenacThe serum concentration of Lithium can be increased when it is combined with Bromfenac.Approved
BromocriptineThe risk or severity of adverse effects can be increased when Bromocriptine is combined with Lithium.Approved, Investigational
BromperidolLithium may increase the neurotoxic activities of Bromperidol.Investigational
BrompheniramineThe risk or severity of adverse effects can be increased when Lithium is combined with Brompheniramine.Approved
BrotizolamThe risk or severity of adverse effects can be increased when Lithium is combined with Brotizolam.Approved, Withdrawn
BucillamineThe serum concentration of Lithium can be increased when it is combined with Bucillamine.Investigational
BumetanideThe serum concentration of Lithium can be decreased when it is combined with Bumetanide.Approved
BupivacaineThe risk or severity of adverse effects can be increased when Bupivacaine is combined with Lithium.Approved, Investigational
BuprenorphineLithium may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.Approved, Illicit, Investigational, Vet Approved
BuspironeThe risk or severity of adverse effects can be increased when Buspirone is combined with Lithium.Approved, Investigational
ButabarbitalThe risk or severity of adverse effects can be increased when Butabarbital is combined with Lithium.Approved, Illicit
ButacaineThe risk or severity of adverse effects can be increased when Lithium is combined with Butacaine.Vet Approved
ButalbitalThe risk or severity of adverse effects can be increased when Lithium is combined with Butalbital.Approved, Illicit
ButambenThe risk or severity of adverse effects can be increased when Lithium is combined with Butamben.Approved
ButethalThe risk or severity of adverse effects can be increased when Butethal is combined with Lithium.Approved, Illicit
ButorphanolThe risk or severity of adverse effects can be increased when Butorphanol is combined with Lithium.Approved, Illicit, Vet Approved
CabergolineThe risk or severity of adverse effects can be increased when Cabergoline is combined with Lithium.Approved
CaffeineThe serum concentration of Lithium can be decreased when it is combined with Caffeine.Approved
CandesartanThe serum concentration of Lithium can be increased when it is combined with Candesartan.Approved
CandoxatrilThe serum concentration of Lithium can be increased when it is combined with Candoxatril.Experimental
CaptoprilThe serum concentration of Lithium can be increased when it is combined with Captopril.Approved
CarbamazepineThe risk or severity of adverse effects can be increased when Carbamazepine is combined with Lithium.Approved, Investigational
CarbinoxamineThe risk or severity of adverse effects can be increased when Lithium is combined with Carbinoxamine.Approved
CarfentanilThe risk or severity of adverse effects can be increased when Lithium is combined with Carfentanil.Illicit, Vet Approved
CariprazineLithium may increase the neurotoxic activities of Cariprazine.Approved
CarisoprodolThe risk or severity of adverse effects can be increased when Lithium is combined with Carisoprodol.Approved
CaroxazoneThe risk or severity of adverse effects can be increased when Caroxazone is combined with Lithium.Withdrawn
CarprofenThe serum concentration of Lithium can be increased when it is combined with Carprofen.Approved, Vet Approved, Withdrawn
CastanospermineThe serum concentration of Lithium can be increased when it is combined with Castanospermine.Experimental
CelecoxibThe serum concentration of Lithium can be increased when it is combined with Celecoxib.Approved, Investigational
CeritinibLithium may increase the QTc-prolonging activities of Ceritinib.Approved
CetirizineThe risk or severity of adverse effects can be increased when Lithium is combined with Cetirizine.Approved
Chloral hydrateThe risk or severity of adverse effects can be increased when Lithium is combined with Chloral hydrate.Approved, Illicit, Vet Approved
ChlordiazepoxideThe risk or severity of adverse effects can be increased when Chlordiazepoxide is combined with Lithium.Approved, Illicit
ChlormezanoneThe risk or severity of adverse effects can be increased when Chlormezanone is combined with Lithium.Approved, Withdrawn
ChloroprocaineThe risk or severity of adverse effects can be increased when Chloroprocaine is combined with Lithium.Approved
ChloroquineThe serum concentration of Lithium can be increased when it is combined with Chloroquine.Approved, Vet Approved
ChlorothiazideChlorothiazide may decrease the excretion rate of Lithium which could result in a higher serum level.Approved, Vet Approved
ChlorphenamineThe risk or severity of adverse effects can be increased when Lithium is combined with Chlorphenamine.Approved
ChlorphentermineLithium may decrease the stimulatory activities of Chlorphentermine.Illicit, Withdrawn
ChlorpromazineLithium may increase the neurotoxic activities of Chlorpromazine.Approved, Vet Approved
ChlorprothixeneLithium may increase the neurotoxic activities of Chlorprothixene.Approved, Withdrawn
ChlorthalidoneChlorthalidone may decrease the excretion rate of Lithium which could result in a higher serum level.Approved
ChlorzoxazoneThe risk or severity of adverse effects can be increased when Lithium is combined with Chlorzoxazone.Approved
CilazaprilThe serum concentration of Lithium can be increased when it is combined with Cilazapril.Approved
CinchocaineThe risk or severity of adverse effects can be increased when Cinchocaine is combined with Lithium.Approved, Vet Approved
CiprofloxacinLithium may increase the QTc-prolonging activities of Ciprofloxacin.Approved, Investigational
CisaprideLithium may increase the QTc-prolonging activities of Cisapride.Approved, Investigational, Withdrawn
Cisatracurium besylateLithium may increase the neuromuscular blocking activities of Cisatracurium besylate.Approved
CitalopramLithium may increase the serotonergic activities of Citalopram.Approved
ClarithromycinLithium may increase the QTc-prolonging activities of Clarithromycin.Approved
ClemastineThe risk or severity of adverse effects can be increased when Lithium is combined with Clemastine.Approved
ClidiniumThe risk or severity of adverse effects can be increased when Lithium is combined with Clidinium.Approved
ClobazamThe risk or severity of adverse effects can be increased when Lithium is combined with Clobazam.Approved, Illicit
clomethiazoleThe risk or severity of adverse effects can be increased when Lithium is combined with clomethiazole.Investigational
ClomipramineLithium may increase the neurotoxic activities of Clomipramine.Approved, Vet Approved
ClonazepamThe risk or severity of adverse effects can be increased when Lithium is combined with Clonazepam.Approved, Illicit
ClonidineThe risk or severity of adverse effects can be increased when Lithium is combined with Clonidine.Approved
ClonixinThe serum concentration of Lithium can be increased when it is combined with Clonixin.Approved
ClorazepateThe risk or severity of adverse effects can be increased when Clorazepate is combined with Lithium.Approved, Illicit
ClozapineLithium may increase the neurotoxic activities of Clozapine.Approved
CocaineThe risk or severity of adverse effects can be increased when Cocaine is combined with Lithium.Approved, Illicit
CodeineThe risk or severity of adverse effects can be increased when Codeine is combined with Lithium.Approved, Illicit
CrizotinibLithium may increase the QTc-prolonging activities of Crizotinib.Approved
CurcuminThe serum concentration of Lithium can be increased when it is combined with Curcumin.Investigational
CyamemazineLithium may increase the neurotoxic activities of Cyamemazine.Approved
CyclizineThe risk or severity of adverse effects can be increased when Lithium is combined with Cyclizine.Approved
CyclobenzaprineLithium may increase the neurotoxic activities of Cyclobenzaprine.Approved
CyproheptadineThe risk or severity of adverse effects can be increased when Lithium is combined with Cyproheptadine.Approved
D-LimoneneThe serum concentration of Lithium can be increased when it is combined with D-Limonene.Investigational
DantroleneThe risk or severity of adverse effects can be increased when Lithium is combined with Dantrolene.Approved
DapiprazoleLithium may increase the neurotoxic activities of Dapiprazole.Approved
DapoxetineThe risk or severity of adverse effects can be increased when Dapoxetine is combined with Lithium.Investigational
DecamethoniumLithium may increase the neuromuscular blocking activities of Decamethonium.Approved
deramciclaneThe risk or severity of adverse effects can be increased when Lithium is combined with deramciclane.Investigational
DesfluraneThe risk or severity of adverse effects can be increased when Desflurane is combined with Lithium.Approved
DesipramineLithium may increase the neurotoxic activities of Desipramine.Approved
DesloratadineThe risk or severity of adverse effects can be increased when Lithium is combined with Desloratadine.Approved, Investigational
DesmopressinThe therapeutic efficacy of Desmopressin can be decreased when used in combination with Lithium.Approved
DesvenlafaxineLithium may increase the serotonergic activities of Desvenlafaxine.Approved
DetomidineThe risk or severity of adverse effects can be increased when Lithium is combined with Detomidine.Vet Approved
DexbrompheniramineThe risk or severity of adverse effects can be increased when Lithium is combined with Dexbrompheniramine.Approved
DexmedetomidineThe risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Lithium.Approved, Vet Approved
DextroamphetamineLithium may decrease the stimulatory activities of Dextroamphetamine.Approved, Illicit
DextromethorphanThe risk or severity of adverse effects can be increased when Dextromethorphan is combined with Lithium.Approved
DextromoramideThe risk or severity of adverse effects can be increased when Lithium is combined with Dextromoramide.Experimental, Illicit
DextropropoxypheneThe risk or severity of adverse effects can be increased when Dextropropoxyphene is combined with Lithium.Approved, Illicit, Withdrawn
DezocineThe risk or severity of adverse effects can be increased when Dezocine is combined with Lithium.Approved
DiazepamThe risk or severity of adverse effects can be increased when Diazepam is combined with Lithium.Approved, Illicit, Vet Approved
DiclofenacThe serum concentration of Lithium can be increased when it is combined with Diclofenac.Approved, Vet Approved
DiclofenamideThe serum concentration of Lithium can be decreased when it is combined with Diclofenamide.Approved
DiethylpropionLithium may decrease the stimulatory activities of Diethylpropion.Approved, Illicit
DifenoxinThe risk or severity of adverse effects can be increased when Lithium is combined with Difenoxin.Approved, Illicit
DiflunisalThe serum concentration of Lithium can be increased when it is combined with Diflunisal.Approved
DihydrocodeineThe risk or severity of adverse effects can be increased when Lithium is combined with Dihydrocodeine.Approved, Illicit
DihydroergotamineThe risk or severity of adverse effects can be increased when Dihydroergotamine is combined with Lithium.Approved
DihydroetorphineThe risk or severity of adverse effects can be increased when Lithium is combined with Dihydroetorphine.Experimental, Illicit
DihydromorphineThe risk or severity of adverse effects can be increased when Lithium is combined with Dihydromorphine.Experimental, Illicit
DiltiazemDiltiazem may increase the neurotoxic activities of Lithium.Approved
DimenhydrinateThe risk or severity of adverse effects can be increased when Lithium is combined with Dimenhydrinate.Approved
DiphenhydramineThe risk or severity of adverse effects can be increased when Diphenhydramine is combined with Lithium.Approved
DiphenoxylateThe risk or severity of adverse effects can be increased when Diphenoxylate is combined with Lithium.Approved, Illicit
DisopyramideLithium may increase the QTc-prolonging activities of Disopyramide.Approved
DofetilideLithium may increase the QTc-prolonging activities of Dofetilide.Approved
DolasetronLithium may increase the QTc-prolonging activities of Dolasetron.Approved
Domoic AcidLithium may increase the neuromuscular blocking activities of Domoic Acid.Experimental
DomperidoneLithium may increase the QTc-prolonging activities of Domperidone.Approved, Investigational, Vet Approved
DoramectinThe risk or severity of adverse effects can be increased when Lithium is combined with Doramectin.Vet Approved
DorzolamideThe serum concentration of Lithium can be decreased when it is combined with Dorzolamide.Approved
DosulepinLithium may increase the neurotoxic activities of Dosulepin.Approved
Doxacurium chlorideLithium may increase the neuromuscular blocking activities of Doxacurium chloride.Approved
DoxepinLithium may increase the neurotoxic activities of Doxepin.Approved
DoxylamineDoxylamine may increase the central nervous system depressant (CNS depressant) activities of Lithium.Approved, Vet Approved
DPDPEThe risk or severity of adverse effects can be increased when Lithium is combined with DPDPE.Investigational
DronabinolDronabinol may increase the central nervous system depressant (CNS depressant) activities of Lithium.Approved, Illicit
DronedaroneLithium may increase the QTc-prolonging activities of Dronedarone.Approved
DroperidolDroperidol may increase the central nervous system depressant (CNS depressant) activities of Lithium.Approved, Vet Approved
DrotebanolThe risk or severity of adverse effects can be increased when Lithium is combined with Drotebanol.Experimental, Illicit
DroxicamThe serum concentration of Lithium can be increased when it is combined with Droxicam.Approved
DuloxetineLithium may increase the serotonergic activities of Duloxetine.Approved
DuvelisibThe serum concentration of Lithium can be increased when it is combined with Duvelisib.Investigational
DyclonineThe risk or severity of adverse effects can be increased when Dyclonine is combined with Lithium.Approved
DyphyllineThe serum concentration of Lithium can be decreased when it is combined with Dyphylline.Approved
E6201The serum concentration of Lithium can be increased when it is combined with E6201.Investigational
EbselenThe serum concentration of Lithium can be increased when it is combined with Ebselen.Investigational
EcgonineThe risk or severity of adverse effects can be increased when Lithium is combined with Ecgonine.Experimental, Illicit
ECGONINE METHYL ESTERThe risk or severity of adverse effects can be increased when Lithium is combined with ECGONINE METHYL ESTER.Experimental
EcopipamLithium may increase the neurotoxic activities of Ecopipam.Investigational
EfavirenzThe risk or severity of adverse effects can be increased when Lithium is combined with Efavirenz.Approved, Investigational
EletriptanThe risk or severity of adverse effects can be increased when Eletriptan is combined with Lithium.Approved, Investigational
EliglustatLithium may increase the QTc-prolonging activities of Eliglustat.Approved
EnalaprilThe serum concentration of Lithium can be increased when it is combined with Enalapril.Approved, Vet Approved
EnalaprilatThe serum concentration of Lithium can be increased when it is combined with Enalaprilat.Approved
EnfluraneThe risk or severity of adverse effects can be increased when Enflurane is combined with Lithium.Approved, Vet Approved
EntacaponeThe risk or severity of adverse effects can be increased when Lithium is combined with Entacapone.Approved, Investigational
EpirizoleThe serum concentration of Lithium can be increased when it is combined with Epirizole.Approved
EplerenoneThe serum concentration of Lithium can be increased when it is combined with Eplerenone.Approved
EprosartanThe serum concentration of Lithium can be increased when it is combined with Eprosartan.Approved
Ergoloid mesylateThe risk or severity of adverse effects can be increased when Ergoloid mesylate is combined with Lithium.Approved
ErgonovineThe risk or severity of adverse effects can be increased when Ergonovine is combined with Lithium.Approved
ErgotamineThe risk or severity of adverse effects can be increased when Ergotamine is combined with Lithium.Approved
ErythromycinLithium may increase the QTc-prolonging activities of Erythromycin.Approved, Vet Approved
EscitalopramLithium may increase the serotonergic activities of Escitalopram.Approved, Investigational
EsmirtazapineLithium may increase the neurotoxic activities of Esmirtazapine.Investigational
EstazolamThe risk or severity of adverse effects can be increased when Estazolam is combined with Lithium.Approved, Illicit
EszopicloneThe risk or severity of adverse effects can be increased when Eszopiclone is combined with Lithium.Approved
Etacrynic acidThe serum concentration of Lithium can be decreased when it is combined with Etacrynic acid.Approved
EtanerceptThe serum concentration of Lithium can be increased when it is combined with Etanercept.Approved, Investigational
EthanolLithium may increase the central nervous system depressant (CNS depressant) activities of Ethanol.Approved
EthchlorvynolThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Lithium.Approved, Illicit, Withdrawn
EthosuximideThe risk or severity of adverse effects can be increased when Lithium is combined with Ethosuximide.Approved
EthotoinThe risk or severity of adverse effects can be increased when Lithium is combined with Ethotoin.Approved
EthoxzolamideThe serum concentration of Lithium can be decreased when it is combined with Ethoxzolamide.Withdrawn
Ethyl carbamateThe risk or severity of adverse effects can be increased when Lithium is combined with Ethyl carbamate.Withdrawn
Ethyl loflazepateThe risk or severity of adverse effects can be increased when Lithium is combined with Ethyl loflazepate.Approved, Illicit
EthylmorphineThe risk or severity of adverse effects can be increased when Lithium is combined with Ethylmorphine.Approved, Illicit
EtidocaineThe risk or severity of adverse effects can be increased when Lithium is combined with Etidocaine.Approved
EtifoxineThe risk or severity of adverse effects can be increased when Lithium is combined with Etifoxine.Withdrawn
EtizolamThe risk or severity of adverse effects can be increased when Lithium is combined with Etizolam.Approved
EtodolacThe serum concentration of Lithium can be increased when it is combined with Etodolac.Approved, Investigational, Vet Approved
EtofenamateThe serum concentration of Lithium can be increased when it is combined with Etofenamate.Approved
EtomidateThe risk or severity of adverse effects can be increased when Etomidate is combined with Lithium.Approved
EtoperidoneLithium may increase the serotonergic activities of Etoperidone.Approved
EtoricoxibThe serum concentration of Lithium can be increased when it is combined with Etoricoxib.Approved, Investigational
EtorphineThe risk or severity of adverse effects can be increased when Lithium is combined with Etorphine.Illicit, Vet Approved
Evening primrose oilThe serum concentration of Lithium can be increased when it is combined with Evening primrose oil.Approved
exisulindThe serum concentration of Lithium can be increased when it is combined with exisulind.Investigational
EzogabineThe risk or severity of adverse effects can be increased when Lithium is combined with Ezogabine.Approved
FelbamateThe risk or severity of adverse effects can be increased when Lithium is combined with Felbamate.Approved
FenbufenThe serum concentration of Lithium can be increased when it is combined with Fenbufen.Approved
FencamfamineLithium may increase the neurotoxic activities of Fencamfamine.Approved, Illicit, Withdrawn
FenoprofenThe serum concentration of Lithium can be increased when it is combined with Fenoprofen.Approved
FentanylThe risk or severity of adverse effects can be increased when Fentanyl is combined with Lithium.Approved, Illicit, Investigational, Vet Approved
FexofenadineThe risk or severity of adverse effects can be increased when Lithium is combined with Fexofenadine.Approved
FlecainideLithium may increase the QTc-prolonging activities of Flecainide.Approved, Withdrawn
FlibanserinThe risk or severity of adverse effects can be increased when Lithium is combined with Flibanserin.Approved
FloctafenineThe serum concentration of Lithium can be increased when it is combined with Floctafenine.Approved, Withdrawn
FludiazepamThe risk or severity of adverse effects can be increased when Lithium is combined with Fludiazepam.Approved, Illicit
FlunarizineThe risk or severity of adverse effects can be increased when Lithium is combined with Flunarizine.Approved
FlunitrazepamThe risk or severity of adverse effects can be increased when Lithium is combined with Flunitrazepam.Approved, Illicit
FlunixinThe serum concentration of Lithium can be increased when it is combined with Flunixin.Vet Approved
FluoxetineLithium may increase the serotonergic activities of Fluoxetine.Approved, Vet Approved
FlupentixolLithium may increase the neurotoxic activities of Flupentixol.Approved, Withdrawn
FluphenazineLithium may increase the neurotoxic activities of Fluphenazine.Approved
FlurazepamThe risk or severity of adverse effects can be increased when Flurazepam is combined with Lithium.Approved, Illicit
FlurbiprofenThe serum concentration of Lithium can be increased when it is combined with Flurbiprofen.Approved, Investigational
FluspirileneLithium may increase the neurotoxic activities of Fluspirilene.Approved
Fluticasone PropionateThe risk or severity of adverse effects can be increased when Lithium is combined with Fluticasone Propionate.Approved
FluvoxamineLithium may increase the serotonergic activities of Fluvoxamine.Approved, Investigational
ForasartanThe serum concentration of Lithium can be increased when it is combined with Forasartan.Experimental
FosinoprilThe serum concentration of Lithium can be increased when it is combined with Fosinopril.Approved
FosphenytoinThe risk or severity of adverse effects can be increased when Fosphenytoin is combined with Lithium.Approved
FospropofolThe risk or severity of adverse effects can be increased when Lithium is combined with Fospropofol.Approved, Illicit
FrovatriptanThe risk or severity of adverse effects can be increased when Frovatriptan is combined with Lithium.Approved, Investigational
FurazolidoneThe risk or severity of adverse effects can be increased when Furazolidone is combined with Lithium.Approved, Vet Approved
FurosemideThe serum concentration of Lithium can be decreased when it is combined with Furosemide.Approved, Vet Approved
GabapentinThe risk or severity of adverse effects can be increased when Gabapentin is combined with Lithium.Approved, Investigational
gabapentin enacarbilThe risk or severity of adverse effects can be increased when Lithium is combined with gabapentin enacarbil.Approved
Gadobenic acidLithium may increase the QTc-prolonging activities of Gadobenic acid.Approved
Gallamine TriethiodideLithium may increase the neuromuscular blocking activities of Gallamine Triethiodide.Approved
Gamma Hydroxybutyric AcidThe risk or severity of adverse effects can be increased when Lithium is combined with Gamma Hydroxybutyric Acid.Approved, Illicit
GemifloxacinLithium may increase the QTc-prolonging activities of Gemifloxacin.Approved, Investigational
GepironeThe risk or severity of adverse effects can be increased when Lithium is combined with Gepirone.Investigational
GlutethimideThe risk or severity of adverse effects can be increased when Lithium is combined with Glutethimide.Approved, Illicit
GoserelinLithium may increase the QTc-prolonging activities of Goserelin.Approved
GranisetronLithium may increase the QTc-prolonging activities of Granisetron.Approved, Investigational
GuanfacineThe risk or severity of adverse effects can be increased when Lithium is combined with Guanfacine.Approved, Investigational
HalazepamThe risk or severity of adverse effects can be increased when Halazepam is combined with Lithium.Approved, Illicit, Withdrawn
HaloperidolLithium may increase the neurotoxic activities of Haloperidol.Approved
HalothaneThe risk or severity of adverse effects can be increased when Halothane is combined with Lithium.Approved, Vet Approved
HeroinThe risk or severity of adverse effects can be increased when Lithium is combined with Heroin.Approved, Illicit
HexobarbitalThe risk or severity of adverse effects can be increased when Hexobarbital is combined with Lithium.Approved
HigenamineThe serum concentration of Lithium can be increased when it is combined with Higenamine.Investigational
HMPL-004The serum concentration of Lithium can be increased when it is combined with HMPL-004.Investigational
Human calcitoninThe serum concentration of Lithium can be decreased when it is combined with Human calcitonin.Approved
HydracarbazineThe risk or severity of adverse effects can be increased when Hydracarbazine is combined with Lithium.Approved
HydrochlorothiazideHydrochlorothiazide may decrease the excretion rate of Lithium which could result in a higher serum level.Approved, Vet Approved
HydrocodoneLithium may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved, Illicit
HydroflumethiazideHydroflumethiazide may decrease the excretion rate of Lithium which could result in a higher serum level.Approved
HydromorphoneThe risk or severity of adverse effects can be increased when Hydromorphone is combined with Lithium.Approved, Illicit
Hydroxyamphetamine hydrobromideLithium may decrease the stimulatory activities of Hydroxyamphetamine hydrobromide.Approved
HydroxyzineHydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Lithium.Approved
IbuprofenThe serum concentration of Lithium can be increased when it is combined with Ibuprofen.Approved
IbuproxamThe serum concentration of Lithium can be increased when it is combined with Ibuproxam.Withdrawn
IbutilideLithium may increase the QTc-prolonging activities of Ibutilide.Approved
IcatibantThe serum concentration of Lithium can be increased when it is combined with Icatibant.Approved
IloperidoneLithium may increase the neurotoxic activities of Iloperidone.Approved
ImidaprilThe serum concentration of Lithium can be increased when it is combined with Imidapril.Investigational
ImipramineLithium may increase the neurotoxic activities of Imipramine.Approved
IndalpineLithium may increase the serotonergic activities of Indalpine.Investigational, Withdrawn
IndapamideIndapamide may decrease the excretion rate of Lithium which could result in a higher serum level.Approved
IndomethacinThe serum concentration of Lithium can be increased when it is combined with Indomethacin.Approved, Investigational
IndoprofenThe serum concentration of Lithium can be increased when it is combined with Indoprofen.Withdrawn
IproclozideThe risk or severity of adverse effects can be increased when Iproclozide is combined with Lithium.Withdrawn
IproniazidThe risk or severity of adverse effects can be increased when Iproniazid is combined with Lithium.Withdrawn
IrbesartanThe serum concentration of Lithium can be increased when it is combined with Irbesartan.Approved, Investigational
IsocarboxazidThe risk or severity of adverse effects can be increased when Isocarboxazid is combined with Lithium.Approved
IsofluraneThe risk or severity of adverse effects can be increased when Isoflurane is combined with Lithium.Approved, Vet Approved
IsoxicamThe serum concentration of Lithium can be increased when it is combined with Isoxicam.Withdrawn
KebuzoneThe serum concentration of Lithium can be increased when it is combined with Kebuzone.Experimental
KetamineThe risk or severity of adverse effects can be increased when Ketamine is combined with Lithium.Approved, Vet Approved
KetazolamThe risk or severity of adverse effects can be increased when Lithium is combined with Ketazolam.Approved
KetobemidoneThe risk or severity of adverse effects can be increased when Lithium is combined with Ketobemidone.Approved
KetoprofenThe serum concentration of Lithium can be increased when it is combined with Ketoprofen.Approved, Vet Approved
KetorolacThe serum concentration of Lithium can be increased when it is combined with Ketorolac.Approved
LamotrigineThe risk or severity of adverse effects can be increased when Lithium is combined with Lamotrigine.Approved, Investigational
LeflunomideThe serum concentration of Lithium can be increased when it is combined with Leflunomide.Approved, Investigational
LenvatinibLithium may increase the QTc-prolonging activities of Lenvatinib.Approved
LeuprolideLithium may increase the QTc-prolonging activities of Leuprolide.Approved, Investigational
LevetiracetamThe risk or severity of adverse effects can be increased when Lithium is combined with Levetiracetam.Approved, Investigational
LevobupivacaineThe risk or severity of adverse effects can be increased when Levobupivacaine is combined with Lithium.Approved
LevocabastineThe risk or severity of adverse effects can be increased when Lithium is combined with Levocabastine.Approved
LevocetirizineThe risk or severity of adverse effects can be increased when Lithium is combined with Levocetirizine.Approved
LevodopaThe risk or severity of adverse effects can be increased when Lithium is combined with Levodopa.Approved
LevofloxacinLithium may increase the QTc-prolonging activities of Levofloxacin.Approved, Investigational
Levomethadyl AcetateThe risk or severity of adverse effects can be increased when Levomethadyl Acetate is combined with Lithium.Approved
LevomilnacipranLithium may increase the serotonergic activities of Levomilnacipran.Approved
LevorphanolThe risk or severity of adverse effects can be increased when Levorphanol is combined with Lithium.Approved
LidocaineThe risk or severity of adverse effects can be increased when Lidocaine is combined with Lithium.Approved, Vet Approved
LinezolidThe risk or severity of adverse effects can be increased when Linezolid is combined with Lithium.Approved, Investigational
LisdexamfetamineLithium may decrease the stimulatory activities of Lisdexamfetamine.Approved, Investigational
LisinoprilThe serum concentration of Lithium can be increased when it is combined with Lisinopril.Approved, Investigational
LisofyllineThe serum concentration of Lithium can be increased when it is combined with Lisofylline.Investigational
LofentanilThe risk or severity of adverse effects can be increased when Lithium is combined with Lofentanil.Illicit
LopinavirLithium may increase the QTc-prolonging activities of Lopinavir.Approved
LoratadineThe risk or severity of adverse effects can be increased when Lithium is combined with Loratadine.Approved
LorazepamThe risk or severity of adverse effects can be increased when Lorazepam is combined with Lithium.Approved
LorcaserinThe risk or severity of adverse effects can be increased when Lithium is combined with Lorcaserin.Approved
LornoxicamThe serum concentration of Lithium can be increased when it is combined with Lornoxicam.Approved
LosartanThe serum concentration of Lithium can be increased when it is combined with Losartan.Approved
LoxapineLithium may increase the neurotoxic activities of Loxapine.Approved
LoxoprofenThe serum concentration of Lithium can be increased when it is combined with Loxoprofen.Approved
Lu AA21004The risk or severity of adverse effects can be increased when Lithium is combined with Lu AA21004.Investigational
LumefantrineLithium may increase the QTc-prolonging activities of Lumefantrine.Approved
LumiracoxibThe serum concentration of Lithium can be increased when it is combined with Lumiracoxib.Approved, Investigational
LurasidoneLithium may increase the neurotoxic activities of Lurasidone.Approved
Magnesium salicylateThe serum concentration of Lithium can be increased when it is combined with Magnesium salicylate.Approved
Magnesium SulfateMagnesium Sulfate may increase the central nervous system depressant (CNS depressant) activities of Lithium.Approved, Vet Approved
MaprotilineThe risk or severity of adverse effects can be increased when Maprotiline is combined with Lithium.Approved
MasoprocolThe serum concentration of Lithium can be increased when it is combined with Masoprocol.Approved
MebanazineThe risk or severity of adverse effects can be increased when Mebanazine is combined with Lithium.Withdrawn
MeclizineThe risk or severity of adverse effects can be increased when Lithium is combined with Meclizine.Approved
Meclofenamic acidThe serum concentration of Lithium can be increased when it is combined with Meclofenamic acid.Approved, Vet Approved
MedetomidineThe risk or severity of adverse effects can be increased when Lithium is combined with Medetomidine.Vet Approved
Mefenamic acidThe serum concentration of Lithium can be increased when it is combined with Mefenamic acid.Approved
MelatoninThe risk or severity of adverse effects can be increased when Melatonin is combined with Lithium.Approved, Nutraceutical, Vet Approved
MeloxicamThe serum concentration of Lithium can be increased when it is combined with Meloxicam.Approved, Vet Approved
MelperoneLithium may increase the neurotoxic activities of Melperone.Approved
MephedroneLithium may decrease the stimulatory activities of Mephedrone.Investigational
MephentermineLithium may decrease the stimulatory activities of Mephentermine.Approved
MepivacaineThe risk or severity of adverse effects can be increased when Mepivacaine is combined with Lithium.Approved, Vet Approved
MeprobamateThe risk or severity of adverse effects can be increased when Meprobamate is combined with Lithium.Approved, Illicit
MequitazineLithium may increase the arrhythmogenic activities of Mequitazine.Approved
MesalazineThe serum concentration of Lithium can be increased when it is combined with Mesalazine.Approved
MesoridazineLithium may increase the neurotoxic activities of Mesoridazine.Approved
MetamizoleThe serum concentration of Lithium can be increased when it is combined with Metamizole.Withdrawn
MetaxaloneThe risk or severity of adverse effects can be increased when Lithium is combined with Metaxalone.Approved
MethadoneThe risk or severity of adverse effects can be increased when Methadone is combined with Lithium.Approved
Methadyl AcetateThe risk or severity of adverse effects can be increased when Lithium is combined with Methadyl Acetate.Approved, Illicit
MethamphetamineLithium may decrease the stimulatory activities of Methamphetamine.Approved, Illicit
MethapyrileneThe risk or severity of adverse effects can be increased when Lithium is combined with Methapyrilene.Withdrawn
MethaqualoneThe risk or severity of adverse effects can be increased when Lithium is combined with Methaqualone.Illicit, Withdrawn
MethazolamideThe serum concentration of Lithium can be decreased when it is combined with Methazolamide.Approved
MethocarbamolThe risk or severity of adverse effects can be increased when Lithium is combined with Methocarbamol.Approved, Vet Approved
MethohexitalThe risk or severity of adverse effects can be increased when Methohexital is combined with Lithium.Approved
MethotrimeprazineLithium may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.Approved
MethoxyfluraneThe risk or severity of adverse effects can be increased when Methoxyflurane is combined with Lithium.Approved, Vet Approved
MethsuximideThe risk or severity of adverse effects can be increased when Lithium is combined with Methsuximide.Approved
MethyclothiazideMethyclothiazide may decrease the excretion rate of Lithium which could result in a higher serum level.Approved
MethyldopaThe risk or severity of adverse effects can be increased when Methyldopa is combined with Lithium.Approved
Methylene blueThe risk or severity of adverse effects can be increased when Methylene blue is combined with Lithium.Investigational
MethylphenidateThe risk or severity of adverse effects can be increased when Lithium is combined with Methylphenidate.Approved, Investigational
MethylphenobarbitalThe risk or severity of adverse effects can be increased when Methylphenobarbital is combined with Lithium.Approved
MetoclopramideThe risk or severity of adverse effects can be increased when Metoclopramide is combined with Lithium.Approved, Investigational
MetocurineLithium may increase the neuromuscular blocking activities of Metocurine.Approved
Metocurine IodideLithium may increase the neuromuscular blocking activities of Metocurine Iodide.Withdrawn
MetolazoneMetolazone may decrease the excretion rate of Lithium which could result in a higher serum level.Approved
MetyrosineLithium may increase the sedative activities of Metyrosine.Approved
MidazolamThe risk or severity of adverse effects can be increased when Midazolam is combined with Lithium.Approved, Illicit
MifepristoneMifepristone may increase the QTc-prolonging activities of Lithium.Approved, Investigational
MilnacipranLithium may increase the serotonergic activities of Milnacipran.Approved
MinaprineThe risk or severity of adverse effects can be increased when Minaprine is combined with Lithium.Approved
MinocyclineMinocycline may increase the central nervous system depressant (CNS depressant) activities of Lithium.Approved, Investigational
MirtazapineLithium may increase the neurotoxic activities of Mirtazapine.Approved
MivacuriumLithium may increase the neuromuscular blocking activities of Mivacurium.Approved
MizoribineThe serum concentration of Lithium can be increased when it is combined with Mizoribine.Investigational
MMDALithium may decrease the stimulatory activities of MMDA.Experimental, Illicit
MoclobemideThe risk or severity of adverse effects can be increased when Moclobemide is combined with Lithium.Approved
MoexiprilThe serum concentration of Lithium can be increased when it is combined with Moexipril.Approved
MolindoneLithium may increase the neurotoxic activities of Molindone.Approved
MorphineThe risk or severity of adverse effects can be increased when Morphine is combined with Lithium.Approved, Investigational
MoxifloxacinLithium may increase the QTc-prolonging activities of Moxifloxacin.Approved, Investigational
Mycophenolate mofetilThe serum concentration of Lithium can be increased when it is combined with Mycophenolate mofetil.Approved, Investigational
Mycophenolic acidThe serum concentration of Lithium can be increased when it is combined with Mycophenolic acid.Approved
NabiloneNabilone may increase the central nervous system depressant (CNS depressant) activities of Lithium.Approved, Investigational
NabumetoneThe serum concentration of Lithium can be increased when it is combined with Nabumetone.Approved
NafamostatThe serum concentration of Lithium can be increased when it is combined with Nafamostat.Investigational
NaftifineThe serum concentration of Lithium can be increased when it is combined with Naftifine.Approved
NalbuphineThe risk or severity of adverse effects can be increased when Nalbuphine is combined with Lithium.Approved
NaproxenThe serum concentration of Lithium can be increased when it is combined with Naproxen.Approved, Vet Approved
NaratriptanThe risk or severity of adverse effects can be increased when Naratriptan is combined with Lithium.Approved, Investigational
NCX 4016The serum concentration of Lithium can be increased when it is combined with NCX 4016.Investigational
NefazodoneLithium may increase the serotonergic activities of Nefazodone.Approved, Withdrawn
NeosaxitoxinLithium may increase the neuromuscular blocking activities of Neosaxitoxin.Investigational
NepafenacThe serum concentration of Lithium can be increased when it is combined with Nepafenac.Approved
NialamideThe risk or severity of adverse effects can be increased when Nialamide is combined with Lithium.Withdrawn
Niflumic AcidThe serum concentration of Lithium can be increased when it is combined with Niflumic Acid.Approved
NilotinibLithium may increase the QTc-prolonging activities of Nilotinib.Approved, Investigational
NimesulideThe serum concentration of Lithium can be increased when it is combined with Nimesulide.Approved, Withdrawn
NitrazepamThe risk or severity of adverse effects can be increased when Lithium is combined with Nitrazepam.Approved
NitroaspirinThe serum concentration of Lithium can be increased when it is combined with Nitroaspirin.Investigational
Nitrous oxideThe risk or severity of adverse effects can be increased when Lithium is combined with Nitrous oxide.Approved, Vet Approved
NormethadoneThe risk or severity of adverse effects can be increased when Lithium is combined with Normethadone.Approved, Illicit
NortriptylineLithium may increase the neurotoxic activities of Nortriptyline.Approved
OctamoxinThe risk or severity of adverse effects can be increased when Octamoxin is combined with Lithium.Withdrawn
OfloxacinLithium may increase the QTc-prolonging activities of Ofloxacin.Approved
OlanzapineLithium may increase the neurotoxic activities of Olanzapine.Approved, Investigational
OlmesartanThe serum concentration of Lithium can be increased when it is combined with Olmesartan.Approved, Investigational
OlopatadineThe serum concentration of Lithium can be increased when it is combined with Olopatadine.Approved
OlsalazineThe serum concentration of Lithium can be increased when it is combined with Olsalazine.Approved
OmapatrilatThe serum concentration of Lithium can be increased when it is combined with Omapatrilat.Investigational
OndansetronLithium may increase the neurotoxic activities of Ondansetron.Approved
OpipramolLithium may increase the neurotoxic activities of Opipramol.Investigational
OpiumThe risk or severity of adverse effects can be increased when Lithium is combined with Opium.Approved, Illicit
OrgoteinThe serum concentration of Lithium can be increased when it is combined with Orgotein.Vet Approved
OrphenadrineLithium may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.Approved
OsanetantLithium may increase the neurotoxic activities of Osanetant.Investigational
OxaprozinThe serum concentration of Lithium can be increased when it is combined with Oxaprozin.Approved
OxazepamThe risk or severity of adverse effects can be increased when Oxazepam is combined with Lithium.Approved
OxetacaineThe risk or severity of adverse effects can be increased when Lithium is combined with Oxetacaine.Investigational
OxprenololThe risk or severity of adverse effects can be increased when Lithium is combined with Oxprenolol.Approved
OxybuprocaineThe risk or severity of adverse effects can be increased when Oxybuprocaine is combined with Lithium.Approved
OxycodoneThe risk or severity of adverse effects can be increased when Oxycodone is combined with Lithium.Approved, Illicit, Investigational
OxymorphoneThe risk or severity of adverse effects can be increased when Oxymorphone is combined with Lithium.Approved, Investigational, Vet Approved
OxyphenbutazoneThe serum concentration of Lithium can be increased when it is combined with Oxyphenbutazone.Withdrawn
PaliperidoneLithium may increase the neurotoxic activities of Paliperidone.Approved
PalonosetronPalonosetron may increase the serotonergic activities of Lithium.Approved, Investigational
PancuroniumLithium may increase the neuromuscular blocking activities of Pancuronium.Approved
PanobinostatLithium may increase the QTc-prolonging activities of Panobinostat.Approved, Investigational
ParaldehydeLithium may increase the central nervous system depressant (CNS depressant) activities of Paraldehyde.Approved
ParecoxibThe serum concentration of Lithium can be increased when it is combined with Parecoxib.Approved
PargylineThe risk or severity of adverse effects can be increased when Pargyline is combined with Lithium.Approved
ParoxetineLithium may increase the serotonergic activities of Paroxetine.Approved, Investigational
PazopanibLithium may increase the QTc-prolonging activities of Pazopanib.Approved
PentamidineLithium may increase the QTc-prolonging activities of Pentamidine.Approved
PentazocineThe risk or severity of adverse effects can be increased when Pentazocine is combined with Lithium.Approved, Vet Approved
PentobarbitalThe risk or severity of adverse effects can be increased when Pentobarbital is combined with Lithium.Approved, Vet Approved
PerampanelPerampanel may increase the central nervous system depressant (CNS depressant) activities of Lithium.Approved
PerazineLithium may increase the neurotoxic activities of Perazine.Investigational
PerflutrenLithium may increase the QTc-prolonging activities of Perflutren.Approved
PerindoprilThe serum concentration of Lithium can be increased when it is combined with Perindopril.Approved
PerospironeLithium may increase the neurotoxic activities of Perospirone.Approved
PerphenazineLithium may increase the neurotoxic activities of Perphenazine.Approved
PethidineThe risk or severity of adverse effects can be increased when Pethidine is combined with Lithium.Approved
PhenelzineThe risk or severity of adverse effects can be increased when Phenelzine is combined with Lithium.Approved
PheniprazineThe risk or severity of adverse effects can be increased when Pheniprazine is combined with Lithium.Withdrawn
PhenobarbitalThe risk or severity of adverse effects can be increased when Phenobarbital is combined with Lithium.Approved
PhenoxyethanolThe risk or severity of adverse effects can be increased when Lithium is combined with Phenoxyethanol.Approved
PhenoxypropazineThe risk or severity of adverse effects can be increased when Phenoxypropazine is combined with Lithium.Withdrawn
PhentermineLithium may decrease the stimulatory activities of Phentermine.Approved, Illicit
PhenylbutazoneThe serum concentration of Lithium can be increased when it is combined with Phenylbutazone.Approved, Vet Approved
PhenytoinThe risk or severity of adverse effects can be increased when Phenytoin is combined with Lithium.Approved, Vet Approved
PimecrolimusThe serum concentration of Lithium can be increased when it is combined with Pimecrolimus.Approved, Investigational
PimozideLithium may increase the neurotoxic activities of Pimozide.Approved
PipamperoneLithium may increase the neurotoxic activities of Pipamperone.Approved
PipecuroniumLithium may increase the neuromuscular blocking activities of Pipecuronium.Approved
PipotiazineLithium may increase the neurotoxic activities of Pipotiazine.Approved
PiretanideThe serum concentration of Lithium can be decreased when it is combined with Piretanide.Experimental
PirfenidoneThe serum concentration of Lithium can be increased when it is combined with Pirfenidone.Investigational
PiritramideThe risk or severity of adverse effects can be increased when Lithium is combined with Piritramide.Investigational
PirlindoleThe risk or severity of adverse effects can be increased when Pirlindole is combined with Lithium.Approved
PiroxicamThe serum concentration of Lithium can be increased when it is combined with Piroxicam.Approved, Investigational
PivhydrazineThe risk or severity of adverse effects can be increased when Pivhydrazine is combined with Lithium.Withdrawn
PizotifenThe risk or severity of adverse effects can be increased when Lithium is combined with Pizotifen.Approved
Polystyrene sulfonateThe serum concentration of Lithium can be decreased when it is combined with Polystyrene sulfonate.Approved
PolythiazidePolythiazide may decrease the excretion rate of Lithium which could result in a higher serum level.Approved
PomalidomideThe risk or severity of adverse effects can be increased when Lithium is combined with Pomalidomide.Approved
Potassium IodidePotassium Iodide may increase the hypothyroid activities of Lithium.Approved
PramipexoleLithium may increase the sedative activities of Pramipexole.Approved, Investigational
PramocaineThe risk or severity of adverse effects can be increased when Lithium is combined with Pramocaine.Approved
PrazepamThe risk or severity of adverse effects can be increased when Lithium is combined with Prazepam.Approved, Illicit
PregabalinThe risk or severity of adverse effects can be increased when Pregabalin is combined with Lithium.Approved, Illicit, Investigational
PregnanoloneThe risk or severity of adverse effects can be increased when Lithium is combined with Pregnanolone.Investigational
PrilocaineThe risk or severity of adverse effects can be increased when Prilocaine is combined with Lithium.Approved
PrimaquineLithium may increase the QTc-prolonging activities of Primaquine.Approved
PrimidoneThe risk or severity of adverse effects can be increased when Lithium is combined with Primidone.Approved, Vet Approved
ProcainamideLithium may increase the QTc-prolonging activities of Procainamide.Approved
ProcaineThe risk or severity of adverse effects can be increased when Procaine is combined with Lithium.Approved, Investigational, Vet Approved
ProcarbazineThe risk or severity of adverse effects can be increased when Procarbazine is combined with Lithium.Approved
ProchlorperazineLithium may increase the neurotoxic activities of Prochlorperazine.Approved, Vet Approved
PromazineLithium may increase the neurotoxic activities of Promazine.Approved, Vet Approved
PromethazineThe risk or severity of adverse effects can be increased when Promethazine is combined with Lithium.Approved
PropacetamolThe serum concentration of Lithium can be increased when it is combined with Propacetamol.Approved
PropafenoneLithium may increase the QTc-prolonging activities of Propafenone.Approved
ProparacaineThe risk or severity of adverse effects can be increased when Proparacaine is combined with Lithium.Approved, Vet Approved
PropericiazineLithium may increase the neurotoxic activities of Propericiazine.Approved
PropofolThe risk or severity of adverse effects can be increased when Propofol is combined with Lithium.Approved, Investigational, Vet Approved
PropoxycaineThe risk or severity of adverse effects can be increased when Lithium is combined with Propoxycaine.Approved
ProthipendylLithium may increase the neurotoxic activities of Prothipendyl.Investigational
ProtriptylineLithium may increase the neurotoxic activities of Protriptyline.Approved
PSD502The risk or severity of adverse effects can be increased when Lithium is combined with PSD502.Investigational
PseudoephedrineLithium may decrease the stimulatory activities of Pseudoephedrine.Approved
PTC299The serum concentration of Lithium can be increased when it is combined with PTC299.Investigational
PyrantelLithium may increase the neuromuscular blocking activities of Pyrantel.Approved, Vet Approved
QuazepamThe risk or severity of adverse effects can be increased when Lithium is combined with Quazepam.Approved, Illicit
QuetiapineLithium may increase the neurotoxic activities of Quetiapine.Approved
QuinagolideThe therapeutic efficacy of Quinagolide can be decreased when used in combination with Lithium.Approved
QuinaprilThe serum concentration of Lithium can be increased when it is combined with Quinapril.Approved, Investigational
QuinethazoneQuinethazone may decrease the excretion rate of Lithium which could result in a higher serum level.Approved
QuinidineLithium may increase the QTc-prolonging activities of Quinidine.Approved
QuinineLithium may increase the QTc-prolonging activities of Quinine.Approved
RacloprideLithium may increase the neurotoxic activities of Raclopride.Investigational
RamelteonThe risk or severity of adverse effects can be increased when Lithium is combined with Ramelteon.Approved, Investigational
RamiprilThe serum concentration of Lithium can be increased when it is combined with Ramipril.Approved
RapacuroniumLithium may increase the neuromuscular blocking activities of Rapacuronium.Withdrawn
RasagilineThe risk or severity of adverse effects can be increased when Rasagiline is combined with Lithium.Approved
RemifentanilThe risk or severity of adverse effects can be increased when Remifentanil is combined with Lithium.Approved
RemoxiprideLithium may increase the neurotoxic activities of Remoxipride.Approved, Withdrawn
RescinnamineThe serum concentration of Lithium can be increased when it is combined with Rescinnamine.Approved
ReserpineLithium may increase the neurotoxic activities of Reserpine.Approved
ResveratrolThe serum concentration of Lithium can be increased when it is combined with Resveratrol.Experimental, Investigational
RisperidoneLithium may increase the neurotoxic activities of Risperidone.Approved, Investigational
RitanserinLithium may increase the neurotoxic activities of Ritanserin.Investigational
RitobegronLithium may decrease the stimulatory activities of Ritobegron.Investigational
RizatriptanThe risk or severity of adverse effects can be increased when Rizatriptan is combined with Lithium.Approved
RocuroniumLithium may increase the neuromuscular blocking activities of Rocuronium.Approved
RofecoxibThe serum concentration of Lithium can be increased when it is combined with Rofecoxib.Investigational, Withdrawn
RomifidineThe risk or severity of adverse effects can be increased when Lithium is combined with Romifidine.Vet Approved
RopiniroleLithium may increase the sedative activities of Ropinirole.Approved, Investigational
RopivacaineThe risk or severity of adverse effects can be increased when Ropivacaine is combined with Lithium.Approved
RotigotineLithium may increase the sedative activities of Rotigotine.Approved
RufinamideThe risk or severity of adverse effects can be increased when Rufinamide is combined with Lithium.Approved
S-EthylisothioureaThe risk or severity of adverse effects can be increased when Lithium is combined with S-Ethylisothiourea.Experimental
SacubitrilThe serum concentration of Lithium can be increased when it is combined with Sacubitril.Approved
SafrazineThe risk or severity of adverse effects can be increased when Safrazine is combined with Lithium.Withdrawn
Sage 547The risk or severity of adverse effects can be increased when Lithium is combined with Sage 547.Investigational
SalicylamideThe serum concentration of Lithium can be increased when it is combined with Salicylamide.Approved
Salicylic acidThe serum concentration of Lithium can be increased when it is combined with Salicylic acid.Approved, Vet Approved
Salmon CalcitoninThe serum concentration of Lithium can be decreased when it is combined with Salmon Calcitonin.Approved, Investigational
SalsalateThe serum concentration of Lithium can be increased when it is combined with Salsalate.Approved
SaprisartanThe serum concentration of Lithium can be increased when it is combined with Saprisartan.Experimental
SaquinavirLithium may increase the QTc-prolonging activities of Saquinavir.Approved, Investigational
SaralasinThe serum concentration of Lithium can be increased when it is combined with Saralasin.Investigational
ScopolamineThe risk or severity of adverse effects can be increased when Lithium is combined with Scopolamine.Approved
SecobarbitalThe risk or severity of adverse effects can be increased when Secobarbital is combined with Lithium.Approved, Vet Approved
SelegilineThe risk or severity of adverse effects can be increased when Selegiline is combined with Lithium.Approved, Investigational, Vet Approved
SeratrodastThe serum concentration of Lithium can be increased when it is combined with Seratrodast.Approved, Investigational
SertindoleLithium may increase the neurotoxic activities of Sertindole.Approved, Withdrawn
SertralineLithium may increase the serotonergic activities of Sertraline.Approved
SevofluraneThe risk or severity of adverse effects can be increased when Sevoflurane is combined with Lithium.Approved, Vet Approved
Sodium bicarbonateSodium bicarbonate may increase the excretion rate of Lithium which could result in a lower serum level and potentially a reduction in efficacy.Approved
Sodium ChlorideSodium Chloride may increase the excretion rate of Lithium which could result in a lower serum level and potentially a reduction in efficacy.Approved, Vet Approved
Sodium oxybateSodium oxybate may increase the central nervous system depressant (CNS depressant) activities of Lithium.Approved
SotalolLithium may increase the QTc-prolonging activities of Sotalol.Approved
SpiraprilThe serum concentration of Lithium can be increased when it is combined with Spirapril.Approved
SRT501The serum concentration of Lithium can be increased when it is combined with SRT501.Investigational
StiripentolThe risk or severity of adverse effects can be increased when Lithium is combined with Stiripentol.Approved
SuccinylcholineLithium may increase the neuromuscular blocking activities of Succinylcholine.Approved
SufentanilThe risk or severity of adverse effects can be increased when Sufentanil is combined with Lithium.Approved, Investigational
SulfasalazineThe serum concentration of Lithium can be increased when it is combined with Sulfasalazine.Approved
SulfisoxazoleLithium may increase the QTc-prolonging activities of Sulfisoxazole.Approved, Vet Approved
SulindacThe serum concentration of Lithium can be increased when it is combined with Sulindac.Approved
SulpirideThe risk or severity of adverse effects can be increased when Lithium is combined with Sulpiride.Approved
SumatriptanThe risk or severity of adverse effects can be increased when Sumatriptan is combined with Lithium.Approved, Investigational
SuprofenThe serum concentration of Lithium can be increased when it is combined with Suprofen.Approved, Withdrawn
SuvorexantLithium may increase the central nervous system depressant (CNS depressant) activities of Suvorexant.Approved
TandospironeThe risk or severity of adverse effects can be increased when Lithium is combined with Tandospirone.Investigational
TapentadolTapentadol may increase the central nervous system depressant (CNS depressant) activities of Lithium.Approved
TasimelteonThe risk or severity of adverse effects can be increased when Lithium is combined with Tasimelteon.Approved
TasosartanThe serum concentration of Lithium can be increased when it is combined with Tasosartan.Approved
Tedizolid PhosphateTedizolid Phosphate may increase the serotonergic activities of Lithium.Approved
TelavancinLithium may increase the QTc-prolonging activities of Telavancin.Approved
TelithromycinLithium may increase the QTc-prolonging activities of Telithromycin.Approved
TelmisartanThe serum concentration of Lithium can be increased when it is combined with Telmisartan.Approved, Investigational
TemazepamThe risk or severity of adverse effects can be increased when Temazepam is combined with Lithium.Approved
TemocaprilThe serum concentration of Lithium can be increased when it is combined with Temocapril.Experimental, Investigational
TenoxicamThe serum concentration of Lithium can be increased when it is combined with Tenoxicam.Approved
TepoxalinThe serum concentration of Lithium can be increased when it is combined with Tepoxalin.Vet Approved
TeriflunomideThe serum concentration of Lithium can be increased when it is combined with Teriflunomide.Approved
TetrabenazineThe risk or severity of adverse effects can be increased when Tetrabenazine is combined with Lithium.Approved
TetracaineThe risk or severity of adverse effects can be increased when Lithium is combined with Tetracaine.Approved, Vet Approved
TetrodotoxinThe risk or severity of adverse effects can be increased when Lithium is combined with Tetrodotoxin.Investigational
ThalidomideLithium may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.Approved, Investigational, Withdrawn
TheophyllineThe serum concentration of Lithium can be decreased when it is combined with Theophylline.Approved
ThiamylalThe risk or severity of adverse effects can be increased when Thiamylal is combined with Lithium.Approved, Vet Approved
ThiopentalThe risk or severity of adverse effects can be increased when Thiopental is combined with Lithium.Approved, Vet Approved
ThioproperazineLithium may increase the neurotoxic activities of Thioproperazine.Approved
ThioridazineLithium may increase the neurotoxic activities of Thioridazine.Approved
ThiothixeneLithium may increase the neurotoxic activities of Thiothixene.Approved
TiagabineThe risk or severity of adverse effects can be increased when Lithium is combined with Tiagabine.Approved
TianeptineLithium may increase the neurotoxic activities of Tianeptine.Approved
TiaprideLithium may increase the neurotoxic activities of Tiapride.Investigational
Tiaprofenic acidThe serum concentration of Lithium can be increased when it is combined with Tiaprofenic acid.Approved
TiletamineThe risk or severity of adverse effects can be increased when Lithium is combined with Tiletamine.Vet Approved
TinoridineThe serum concentration of Lithium can be increased when it is combined with Tinoridine.Investigational
TizanidineThe risk or severity of adverse effects can be increased when Lithium is combined with Tizanidine.Approved
TolcaponeThe risk or severity of adverse effects can be increased when Lithium is combined with Tolcapone.Approved, Withdrawn
Tolfenamic AcidThe serum concentration of Lithium can be increased when it is combined with Tolfenamic Acid.Approved
TolmetinThe serum concentration of Lithium can be increased when it is combined with Tolmetin.Approved
ToloxatoneThe risk or severity of adverse effects can be increased when Toloxatone is combined with Lithium.Approved
TopiramateThe serum concentration of Lithium can be increased when it is combined with Topiramate.Approved
TorasemideThe serum concentration of Lithium can be decreased when it is combined with Torasemide.Approved
ToremifeneLithium may increase the QTc-prolonging activities of Toremifene.Approved, Investigational
TramadolThe risk or severity of adverse effects can be increased when Tramadol is combined with Lithium.Approved, Investigational
TrandolaprilThe serum concentration of Lithium can be increased when it is combined with Trandolapril.Approved
TranilastThe serum concentration of Lithium can be increased when it is combined with Tranilast.Approved, Investigational
Trans-2-PhenylcyclopropylamineThe risk or severity of adverse effects can be increased when Trans-2-Phenylcyclopropylamine is combined with Lithium.Experimental
TranylcypromineThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Lithium.Approved
TrazodoneThe risk or severity of adverse effects can be increased when Trazodone is combined with Lithium.Approved, Investigational
TriazolamThe risk or severity of adverse effects can be increased when Triazolam is combined with Lithium.Approved
TrichlormethiazideTrichlormethiazide may decrease the excretion rate of Lithium which could result in a higher serum level.Approved, Vet Approved
TrifluoperazineLithium may increase the neurotoxic activities of Trifluoperazine.Approved
TriflupromazineLithium may increase the neurotoxic activities of Triflupromazine.Approved, Vet Approved
TrimipramineLithium may increase the neurotoxic activities of Trimipramine.Approved
TriprolidineThe risk or severity of adverse effects can be increased when Lithium is combined with Triprolidine.Approved
Trisalicylate-cholineThe serum concentration of Lithium can be increased when it is combined with Trisalicylate-choline.Approved
TropisetronTropisetron may increase the serotonergic activities of Lithium.Investigational
TubocurarineLithium may increase the neuromuscular blocking activities of Tubocurarine.Approved
Uc1010The risk or severity of adverse effects can be increased when Lithium is combined with Uc1010.Investigational
ValdecoxibThe serum concentration of Lithium can be increased when it is combined with Valdecoxib.Investigational, Withdrawn
Valproic AcidThe risk or severity of adverse effects can be increased when Valproic Acid is combined with Lithium.Approved, Investigational
ValsartanThe serum concentration of Lithium can be increased when it is combined with Valsartan.Approved, Investigational
VandetanibLithium may increase the QTc-prolonging activities of Vandetanib.Approved
VecuroniumLithium may increase the neuromuscular blocking activities of Vecuronium.Approved
VemurafenibLithium may increase the QTc-prolonging activities of Vemurafenib.Approved
VenlafaxineLithium may increase the serotonergic activities of Venlafaxine.Approved
VerapamilVerapamil may increase the neurotoxic activities of Lithium.Approved
VigabatrinThe risk or severity of adverse effects can be increased when Lithium is combined with Vigabatrin.Approved
VilazodoneThe risk or severity of adverse effects can be increased when Lithium is combined with Vilazodone.Approved
VortioxetineThe risk or severity of adverse effects can be increased when Lithium is combined with Vortioxetine.Approved
XylazineThe risk or severity of adverse effects can be increased when Lithium is combined with Xylazine.Vet Approved
ZaleplonThe risk or severity of adverse effects can be increased when Zaleplon is combined with Lithium.Approved, Illicit, Investigational
ZaltoprofenThe serum concentration of Lithium can be increased when it is combined with Zaltoprofen.Approved
ZiconotideThe risk or severity of adverse effects can be increased when Lithium is combined with Ziconotide.Approved
ZileutonThe serum concentration of Lithium can be increased when it is combined with Zileuton.Approved, Investigational, Withdrawn
ZimelidineLithium may increase the serotonergic activities of Zimelidine.Withdrawn
ZiprasidoneLithium may increase the neurotoxic activities of Ziprasidone.Approved
ZolazepamThe risk or severity of adverse effects can be increased when Lithium is combined with Zolazepam.Vet Approved
ZolmitriptanThe risk or severity of adverse effects can be increased when Zolmitriptan is combined with Lithium.Approved, Investigational
ZolpidemLithium may increase the central nervous system depressant (CNS depressant) activities of Zolpidem.Approved
ZomepiracThe serum concentration of Lithium can be increased when it is combined with Zomepirac.Withdrawn
ZonisamideThe risk or severity of adverse effects can be increased when Lithium is combined with Zonisamide.Approved, Investigational
ZopicloneThe risk or severity of adverse effects can be increased when Zopiclone is combined with Lithium.Approved
ZotepineLithium may increase the neurotoxic activities of Zotepine.Approved
ZuclopenthixolLithium may increase the neurotoxic activities of Zuclopenthixol.Approved, Investigational
Food Interactions
  • Avoid alcohol.
  • Avoid excessive quantities of coffee or tea (Caffeine).
  • Avoid iodine supplements.
  • Do not change your salt intake from day to day without telling your doctor.
  • Take with food to reduce irritation. Drink plenty of liquids.
References
Synthesis Reference

Jean-Paul Gabano, “Electrolyte for a lithium/thionyl chloride electric cell, a method of preparing said electrolyte and an electric cell which includes said electrolyte.” U.S. Patent US4375502, issued 0000.

US4375502
General References
  1. Quiroz JA, Machado-Vieira R, Zarate CA Jr, Manji HK: Novel insights into lithium's mechanism of action: neurotrophic and neuroprotective effects. Neuropsychobiology. 2010;62(1):50-60. doi: 10.1159/000314310. Epub 2010 May 7. [PubMed:20453535 ]
External Links
ATC CodesN05AN01
AHFS Codes
  • 28:28.00
  • 92:02.00*
PDB EntriesNot Available
FDA labelDownload (200 KB)
MSDSDownload (72.1 KB)
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.8382
Blood Brain Barrier+0.9708
Caco-2 permeable+0.7056
P-glycoprotein substrateNon-substrate0.8831
P-glycoprotein inhibitor INon-inhibitor0.9869
P-glycoprotein inhibitor IINon-inhibitor0.9855
Renal organic cation transporterNon-inhibitor0.9199
CYP450 2C9 substrateNon-substrate0.8465
CYP450 2D6 substrateNon-substrate0.823
CYP450 3A4 substrateNon-substrate0.8094
CYP450 1A2 substrateNon-inhibitor0.8854
CYP450 2C9 inhibitorNon-inhibitor0.9224
CYP450 2D6 inhibitorNon-inhibitor0.9559
CYP450 2C19 inhibitorNon-inhibitor0.9487
CYP450 3A4 inhibitorNon-inhibitor0.9853
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.9015
Ames testNon AMES toxic0.9663
CarcinogenicityCarcinogens 0.623
BiodegradationReady biodegradable0.9031
Rat acute toxicity2.0881 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9462
hERG inhibition (predictor II)Non-inhibitor0.9716
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Pharmacoeconomics
ManufacturersNot Available
Packagers
Dosage forms
FormRouteStrength
CapsuleOral300 mg
CapsuleOral600 mg
CapsuleOral150 mg
SolutionOral300 mg/5mL
SolutionOral8 meq/5mL
CapsuleOral150 mg/1
CapsuleOral300 mg/1
CapsuleOral600 mg/1
Capsule, gelatin coatedOral150 mg/1
Capsule, gelatin coatedOral300 mg/1
Capsule, gelatin coatedOral600 mg/1
TabletOral300 mg/1
Tablet, extended releaseOral300 mg/1
Tablet, extended releaseOral450 mg/1
Tablet, film coated, extended releaseOral300 mg/1
TabletOral450 mg/1
Tablet, extended releaseOral300 mg
SyrupOral8 mmol
Prices
Unit descriptionCostUnit
Eskalith cr 450 mg tablet0.8USD tablet
Lithium Carbonate 450 mg Controlled Release Tabs0.56USD tab
Lithium Carbonate 300 mg Controlled Release Tabs0.5USD tab
Lithium Carbonate 600 mg capsule0.44USD capsule
Lithium Carbonate 300 mg capsule0.29USD capsule
Lithium Carbonate 300 mg tablet0.29USD tablet
Lithate 20 mg capsule0.28USD capsule
Lithium carb powder reagent0.27USD g
Lithium carbonate 300 mg tab0.22USD each
Lithium Carbonate 150 mg capsule0.21USD capsule
Lithium Citrate 8meq/5ml Syrup0.15USD ml
Lithium citrate 8 meq/5 ml sol0.14USD ml
Pms-Lithium Carbonate 600 mg Capsule0.14USD capsule
Carbolith 150 mg Capsule0.13USD capsule
Lithate 5 mg capsule0.12USD capsule
Lithane 150 mg Capsule0.11USD capsule
Lithane 300 mg Capsule0.11USD capsule
Carbolith 300 mg Capsule0.1USD capsule
Apo-Lithium Carbonate 150 mg Capsule0.06USD capsule
Apo-Lithium Carbonate 300 mg Capsule0.06USD capsule
Pms-Lithium Carbonate 150 mg Capsule0.06USD capsule
Pms-Lithium Carbonate 300 mg Capsule0.06USD capsule
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
PatentsNot Available
Properties
StateSolid
Experimental Properties
PropertyValueSource
melting point0.512 g·cm −3Not Available
Predicted Properties
PropertyValueSource
logP0ChemAxon
Physiological Charge1ChemAxon
Hydrogen Acceptor Count0ChemAxon
Hydrogen Donor Count0ChemAxon
Polar Surface Area0 Å2ChemAxon
Rotatable Bond Count0ChemAxon
Refractivity0 m3·mol-1ChemAxon
Polarizability1.78 Å3ChemAxon
Number of Rings0ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Not Available
Spectra
Spectrum TypeDescriptionSplash Key
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, Positivesplash10-0a4i-9000000000-d37172edddcf6ff27879View in MoNA
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, Positivesplash10-0a4i-9000000000-d37172edddcf6ff27879View in MoNA
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, Positivesplash10-0a4i-9000000000-d37172edddcf6ff27879View in MoNA
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, Negativesplash10-0a4i-9000000000-00619c7d65eb4b7f8f3dView in MoNA
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, Negativesplash10-0a4i-9000000000-00619c7d65eb4b7f8f3dView in MoNA
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, Negativesplash10-0a4i-9000000000-00619c7d65eb4b7f8f3dView in MoNA
Taxonomy
DescriptionThis compound belongs to the class of inorganic compounds known as homogeneous alkali metal compounds. These are inorganic compounds containing only metal atoms,with the largest atom being a alkali metal atom.
KingdomInorganic compounds
Super ClassHomogeneous metal compounds
ClassHomogeneous alkali metal compounds
Sub ClassNot Available
Direct ParentHomogeneous alkali metal compounds
Alternative ParentsNot Available
Substituents
  • Homogeneous alkali metal
  • Acyclic compound
Molecular FrameworkAcyclic compounds
External Descriptors

Targets

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Ubiquitin protein ligase binding
Specific Function:
Constitutively active protein kinase that acts as a negative regulator in the hormonal control of glucose homeostasis, Wnt signaling and regulation of transcription factors and microtubules, by phosphorylating and inactivating glycogen synthase (GYS1 or GYS2), EIF2B, CTNNB1/beta-catenin, APC, AXIN1, DPYSL2/CRMP2, JUN, NFATC1/NFATC, MAPT/TAU and MACF1. Requires primed phosphorylation of the majo...
Gene Name:
GSK3B
Uniprot ID:
P49841
Molecular Weight:
46743.865 Da
References
  1. Borsotto M, Cavarec L, Bouillot M, Romey G, Macciardi F, Delaye A, Nasroune M, Bastucci M, Sambucy JL, Luan JJ, Charpagne A, Jouet V, Leger R, Lazdunski M, Cohen D, Chumakov I: PP2A-Bgamma subunit and KCNQ2 K+ channels in bipolar disorder. Pharmacogenomics J. 2007 Apr;7(2):123-32. Epub 2006 May 30. [PubMed:16733521 ]
  2. Adli M, Hollinde DL, Stamm T, Wiethoff K, Tsahuridu M, Kirchheiner J, Heinz A, Bauer M: Response to lithium augmentation in depression is associated with the glycogen synthase kinase 3-beta -50T/C single nucleotide polymorphism. Biol Psychiatry. 2007 Dec 1;62(11):1295-302. Epub 2007 Jul 12. [PubMed:17628506 ]
  3. O'Brien WT, Klein PS: Validating GSK3 as an in vivo target of lithium action. Biochem Soc Trans. 2009 Oct;37(Pt 5):1133-8. doi: 10.1042/BST0371133. [PubMed:19754466 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Protein homodimerization activity
Specific Function:
Responsible for the provision of inositol required for synthesis of phosphatidylinositol and polyphosphoinositides and has been implicated as the pharmacological target for lithium action in brain. Has broad substrate specificity and can use myo-inositol monophosphates, myo-inositol 1,3-diphosphate, myo-inositol 1,4-diphosphate, scyllo-inositol-phosphate, D-galactose 1-phosphate, glucose-1-phos...
Gene Name:
IMPA1
Uniprot ID:
P29218
Molecular Weight:
30188.59 Da
References
  1. Sarkar S, Rubinsztein DC: Inositol and IP3 levels regulate autophagy: biology and therapeutic speculations. Autophagy. 2006 Apr-Jun;2(2):132-4. Epub 2006 Apr 6. [PubMed:16874097 ]
  2. Trinquet E, Fink M, Bazin H, Grillet F, Maurin F, Bourrier E, Ansanay H, Leroy C, Michaud A, Durroux T, Maurel D, Malhaire F, Goudet C, Pin JP, Naval M, Hernout O, Chretien F, Chapleur Y, Mathis G: D-myo-inositol 1-phosphate as a surrogate of D-myo-inositol 1,4,5-tris phosphate to monitor G protein-coupled receptor activation. Anal Biochem. 2006 Nov 1;358(1):126-35. Epub 2006 Aug 30. [PubMed:16965760 ]
  3. Ohnishi T, Ohba H, Seo KC, Im J, Sato Y, Iwayama Y, Furuichi T, Chung SK, Yoshikawa T: Spatial expression patterns and biochemical properties distinguish a second myo-inositol monophosphatase IMPA2 from IMPA1. J Biol Chem. 2007 Jan 5;282(1):637-46. Epub 2006 Oct 26. [PubMed:17068342 ]
  4. Tanizawa Y, Kuhara A, Inada H, Kodama E, Mizuno T, Mori I: Inositol monophosphatase regulates localization of synaptic components and behavior in the mature nervous system of C. elegans. Genes Dev. 2006 Dec 1;20(23):3296-310. [PubMed:17158747 ]
  5. Ohnishi T, Yamada K, Ohba H, Iwayama Y, Toyota T, Hattori E, Inada T, Kunugi H, Tatsumi M, Ozaki N, Iwata N, Sakamoto K, Iijima Y, Iwata Y, Tsuchiya KJ, Sugihara G, Nanko S, Osumi N, Detera-Wadleigh SD, Kato T, Yoshikawa T: A promoter haplotype of the inositol monophosphatase 2 gene (IMPA2) at 18p11.2 confers a possible risk for bipolar disorder by enhancing transcription. Neuropsychopharmacology. 2007 Aug;32(8):1727-37. Epub 2007 Jan 24. [PubMed:17251911 ]
  6. Li Z, Stieglitz KA, Shrout AL, Wei Y, Weis RM, Stec B, Roberts MF: Mobile loop mutations in an archaeal inositol monophosphatase: modulating three-metal ion assisted catalysis and lithium inhibition. Protein Sci. 2010 Feb;19(2):309-18. doi: 10.1002/pro.315. [PubMed:20027624 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Protein homodimerization activity
Specific Function:
Can use myo-inositol monophosphates, scylloinositol 1,4-diphosphate, glucose-1-phosphate, beta-glycerophosphate, and 2'-AMP as substrates. Has been implicated as the pharmacological target for lithium Li(+) action in brain.
Gene Name:
IMPA2
Uniprot ID:
O14732
Molecular Weight:
31320.525 Da
References
  1. Cryns K, Shamir A, Shapiro J, Daneels G, Goris I, Van Craenendonck H, Straetemans R, Belmaker RH, Agam G, Moechars D, Steckler T: Lack of lithium-like behavioral and molecular effects in IMPA2 knockout mice. Neuropsychopharmacology. 2007 Apr;32(4):881-91. Epub 2006 Jul 12. [PubMed:16841073 ]
  2. Ohnishi T, Ohba H, Seo KC, Im J, Sato Y, Iwayama Y, Furuichi T, Chung SK, Yoshikawa T: Spatial expression patterns and biochemical properties distinguish a second myo-inositol monophosphatase IMPA2 from IMPA1. J Biol Chem. 2007 Jan 5;282(1):637-46. Epub 2006 Oct 26. [PubMed:17068342 ]
  3. Ohnishi T, Yamada K, Ohba H, Iwayama Y, Toyota T, Hattori E, Inada T, Kunugi H, Tatsumi M, Ozaki N, Iwata N, Sakamoto K, Iijima Y, Iwata Y, Tsuchiya KJ, Sugihara G, Nanko S, Osumi N, Detera-Wadleigh SD, Kato T, Yoshikawa T: A promoter haplotype of the inositol monophosphatase 2 gene (IMPA2) at 18p11.2 confers a possible risk for bipolar disorder by enhancing transcription. Neuropsychopharmacology. 2007 Aug;32(8):1727-37. Epub 2007 Jan 24. [PubMed:17251911 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
potentiator
General Function:
Extracellular-glutamate-gated ion channel activity
Specific Function:
Receptor for glutamate that functions as ligand-gated ion channel in the central nervous system and plays an important role in excitatory synaptic transmission. L-glutamate acts as an excitatory neurotransmitter at many synapses in the central nervous system. Binding of the excitatory neurotransmitter L-glutamate induces a conformation change, leading to the opening of the cation channel, and t...
Gene Name:
GRIA3
Uniprot ID:
P42263
Molecular Weight:
101155.975 Da
References
  1. Karkanias NB, Papke RL: Lithium modulates desensitization of the glutamate receptor subtype gluR3 in Xenopus oocytes. Neurosci Lett. 1999 Dec 31;277(3):153-6. [PubMed:10626836 ]
Comments
comments powered by Disqus
Drug created on July 06, 2007 13:50 / Updated on December 08, 2016 11:47